Centro de Pesquisa Clínica Sao Lucas

Hospital PUC-Campinas

Type 2 Diabetes Mellitus

Diabetes Mellitus

Crohn Disease

COVID-19

LY3298176

Dulaglutide

LY2189265

Tirzepatide

LY3009104

Baricitinib

Mirikizumab

Lilly

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.

Study periods for the intervention-specific appendix (ISA) will be as follows:

* A 12-week induction period
* A maintenance period from Week 12 to Week 52, and
* A safety follow-up period up to 16 weeks.

The study will last about 74 weeks and may include up to 19 visits.

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Hospital PUC-Campinas | Centro de Pesquisa Clínica Sao Lucas

Site insights

Work at this site?

Active trials

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)

Trial sponsors